Skip to main content
What types of page to search?

Alternatively use our A-Z index.

Andrew Pettitt

Professor Andrew Pettitt
MA, MB BChir, PhD, MRCP, FRCPath

Ronald Finn Professor of Experimental Medicine and Honorary Consultant Haematologist (Clatterbridge Cancer Centre)
Molecular & Clinical Cancer Medicine

Publications

What type of publication do you want to show?

2024

Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.

Carr, L., Norris, K., Parker, H., Nilsson-Takeuchi, A., Bryant, D., Amarasinghe, H., . . . Strefford, J. C. (2024). Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.. British journal of haematology, 205(5), 2072-2076. doi:10.1111/bjh.19765

DOI
10.1111/bjh.19765
Journal article

Consultations about randomised controlled trials are shorter and less in-depth for socioeconomically disadvantaged patients compared to socioeconomically advantaged patients: qualitative analysis across three trials.

Popa, M., Young, B., Rousseau, N., Cherry, M. G., Jenkins, I., Cloke, J., . . . Sherratt, F. C. (2024). Consultations about randomised controlled trials are shorter and less in-depth for socioeconomically disadvantaged patients compared to socioeconomically advantaged patients: qualitative analysis across three trials.. Trials, 25(1), 382. doi:10.1186/s13063-024-08216-4

DOI
10.1186/s13063-024-08216-4
Journal article

2023

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib

Till, K. J., Abdullah, M., Alnassfan, T., Janet, G. Z., Marks, T., Coma, S., . . . Slupsky, J. R. (2023). Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib. SCIENTIFIC REPORTS, 13(1). doi:10.1038/s41598-023-30148-3

DOI
10.1038/s41598-023-30148-3
Journal article

2022

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Munir, T., Pitchford, A., Bloor, A., Pettitt, A., Patten, P. E. M., Forconi, F., . . . Hillmen, P. (2022). Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study. In BLOOD Vol. 140. doi:10.1182/blood-2022-170463

DOI
10.1182/blood-2022-170463
Conference Paper

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Kersten, M. J., Dreyling, M., Linton, K. M., Chitu, D., Tonino, S., Kap, M., . . . Zijlstra, J. M. (2022). Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial. In BLOOD Vol. 140 (pp. 2283-2285). doi:10.1182/blood-2022-156085

DOI
10.1182/blood-2022-156085
Conference Paper

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Munir, T., Cherrill, L. -R., Webster, N., Dalal, S., Boucher, R. H., Sankhalpara, C., . . . Hillmen, P. (2022). MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study. In BLOOD Vol. 140. doi:10.1182/blood-2022-166700

DOI
10.1182/blood-2022-166700
Conference Paper

Ibrutinib therapy related uveitis: A single-centre case series and literature review

Kalakonda, A. J. M., Jeffers, L., Wells, M., Pettitt, A., Kalakonda, N., Arumainathan, A., . . . Williams, S. (2022). Ibrutinib therapy related uveitis: A single-centre case series and literature review. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 197 (pp. 194). Retrieved from https://www.webofscience.com/

Conference Paper

2021

Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.

Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865

DOI
10.1080/10428194.2021.1876865
Journal article

2020

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.

Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.. Haematologica, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805

DOI
10.3324/haematol.2019.230805
Journal article

A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial

Offner, F., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., . . . Hillmen, P. (2020). A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. BRITISH JOURNAL OF HAEMATOLOGY, 190(5), 736-740. doi:10.1111/bjh.16625

DOI
10.1111/bjh.16625
Journal article

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

Ghia, P., Coutre, S. E., Cheson, B. D., Barrientos, J. C., Hillmen, P., Pettitt, A. R., . . . Furman, R. R. (2020). Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. HAEMATOLOGICA, 105(10), E519-E522. doi:10.3324/haematol.2019.238808

DOI
10.3324/haematol.2019.238808
Journal article

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial

Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805

DOI
10.3324/haematol.2019.230805
Journal article

Clinico-biological significance of DNA methylation in chronic lymphocytic leukaemia patients: results from three UK clinical trials

Rose-Zerilli, M., Wojdacz, T., Amarasinghe, H., Kadalayil, L., Blakemore, S., Parker, H., . . . Strefford, J. (2020). Clinico-biological significance of DNA methylation in chronic lymphocytic leukaemia patients: results from three UK clinical trials. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 100-102). Retrieved from https://www.webofscience.com/

Conference Paper

Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification

Ridout, K., Robbe, P., Cavalieri, D., Alsolami, R., Antoniou, P., Appleby, N., . . . Schuh, A. (2020). Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 167-168). Retrieved from https://www.webofscience.com/

Conference Paper

Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study

Munir, T., Rawstron, A., Brock, K., Munoz-Vicente, S., Yates, F., Bishop, R., . . . Hillmen, P. (2020). Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 227-228). Retrieved from https://www.webofscience.com/

Conference Paper

Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.

Yasin, F., Duckworth, A., Till, K., Pettitt, A., Lin, K., Kalakonda, N., & Slupsky, J. (2020). Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 185-187). Retrieved from https://www.webofscience.com/

Conference Paper

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2020). The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 34(1), 296-300. doi:10.1038/s41375-019-0533-6

DOI
10.1038/s41375-019-0533-6
Journal article

Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.

Linley, A., Kalakonda, N., Forconi, F., Pettitt, A., MacEwan, D., Packham, G., . . . Slupsky, J. (2020). Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 1-2). Retrieved from https://www.webofscience.com/

Conference Paper

2019

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

McCulloch, R., Smith, A., Wainman, B., Ingram, W., Lewis, A., Hawkins, M., . . . Rule, S. (2019). 40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study. In BLOOD Vol. 134. doi:10.1182/blood-2019-128340

DOI
10.1182/blood-2019-128340
Conference Paper

Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia

Allsup, D., Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., . . . Allan, J. M. (2019). Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. In BLOOD Vol. 134. doi:10.1182/blood-2019-122037

DOI
10.1182/blood-2019-122037
Conference Paper

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.

Wojdacz, T. K., Amarasinghe, H. E., Kadalayil, L., Beattie, A., Forster, J., Blakemore, S. J., . . . Strefford, J. C. (2019). Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. BLOOD ADVANCES, 3(16), 2474-2481. doi:10.1182/bloodadvances.2019000237

DOI
10.1182/bloodadvances.2019000237
Journal article

POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES

Till, K. J., Gallardo Zapata, J., Marks, T., Weaver, D. T., Pachter, J. A., Abdullah, M., . . . Slupsky, J. R. (2019). POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES. In Hematological Oncology Vol. 37 (pp. 511-512). Wiley. doi:10.1002/hon.194_2631

DOI
10.1002/hon.194_2631
Conference Paper

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Stilgenbauer, S. (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 37(16), 1391-1402. doi:10.1200/JCO.18.01460

DOI
10.1200/JCO.18.01460
Journal article

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ

Al-Jameel, W., Gou, X., Jin, X., Zhang, J., Wei, Q., Ai, J., . . . Ke, Y. (2019). Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes & Cancer, 10(3-4), 80-96. doi:10.18632/genesandcancer.192

DOI
10.18632/genesandcancer.192
Journal article

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ

Al-Jameel, W., Gou, X., Jin, X., Zhang, J., Wei, Q., Ai, J., . . . Ke, Y. (2019). Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes and Cancer, 10(3-4), 80-96. doi:10.18632/genesandcancer.192

DOI
10.18632/genesandcancer.192
Journal article

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

Offner, F., Robak, T., Janssens, A., Kanakasetty, G. B., Kloczko, J., Grosicki, S., . . . Hillmen, P. (2019). Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/

Conference Paper

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 25). Retrieved from https://www.webofscience.com/

Conference Paper

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 85-86). Retrieved from https://www.webofscience.com/

Conference Paper

2018

Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification

Ridout, K. E., Robbe, P., Cavalieri, D., Becq, J., He, M., Clifford, R., . . . Schuh, A. (2018). Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115935

DOI
10.1182/blood-2018-99-115935
Conference Paper

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Hillmen, P., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Munir, T. (2018). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BLOOD Vol. 132. doi:10.1182/blood-2018-182

DOI
10.1182/blood-2018-182
Conference Paper

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Rawstron, A., Munir, T., Brock, K., Webster, N., Vicente, S. M., Yates, F., . . . Hillmen, P. (2018). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure. In BLOOD Vol. 132. doi:10.1182/blood-2018-181

DOI
10.1182/blood-2018-181
Conference Paper

Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma

McCulloch, R., Berrow, M., Wainman, B., Crosbie, N., Pettitt, A., & Rule, S. (2018). Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-114528

DOI
10.1182/blood-2018-99-114528
Conference Paper

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182(3), 429-433. doi:10.1111/bjh.14793

DOI
10.1111/bjh.14793
Journal article

LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia

Gohil, S. H., Maciocia, N., Patrick, P., Roberts, T., Counsell, N., Smith, P., . . . Nathwani, A. C. (2018). LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 59(7), 1730-1733. doi:10.1080/10428194.2017.1399311

DOI
10.1080/10428194.2017.1399311
Journal article

The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy

Wojdacz, T. K., Amarasinghe, H. E., Rose-Zerilli, M. J. J., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. C. (2018). The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-3306

DOI
10.1158/1538-7445.AM2018-3306
Conference Paper

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.

Alharthi, A., Beck, D., Howard, D. R., Hillmen, P., Oates, M., Pettitt, A., & Wagner, S. D. (2018). An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.. BMC research notes, 11(1), 280. doi:10.1186/s13104-018-3391-9

DOI
10.1186/s13104-018-3391-9
Journal article

Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy

Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 34-35). Retrieved from https://www.webofscience.com/

Conference Paper

Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials

Amarasinghe, H., Wojdacz, T., Rose-Zerilli, M., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. (2018). Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 29). Retrieved from https://www.webofscience.com/

Conference Paper

Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project

Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Burns, A., . . . Schuh, A. (2018). Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 28). Retrieved from https://www.webofscience.com/

Conference Paper

2017

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia

Chapman, E. A., Oates, M., Mohammad, I. S., Davies, B. R., Stockman, P. K., Zhuang, J., & Pettitt, A. R. (2017). Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. Oncotarget, 8(61), 102948-102964. doi:10.18632/oncotarget.22292

DOI
10.18632/oncotarget.22292
Journal article

A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY

Munir, T., Rawstron, A., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY. In HAEMATOLOGICA Vol. 102 (pp. 229-230). Retrieved from https://www.webofscience.com/

Conference Paper

A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Stankovic, T., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Devereux, S. (2017). A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 110-111). Retrieved from https://www.webofscience.com/

Conference Paper

ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY

Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY. In HAEMATOLOGICA Vol. 102 (pp. 69). Retrieved from https://www.webofscience.com/

Conference Paper

Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study

Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 233-234). Retrieved from https://www.webofscience.com/

Conference Paper

DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA

Zinzani, P. L., Wagner-Johnston, N., Miller, C., Ardeshna, K., Tertreault, S., Assouline, S., . . . Flinn, I. (2017). DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA. In HAEMATOLOGICA Vol. 102 (pp. 315). Retrieved from https://www.webofscience.com/

Conference Paper

Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab

Kreuzer, K. -A., Furman, R., Stilgenbauer, S., Dubowy, R., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2017). Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 167-168). Retrieved from https://www.webofscience.com/

Conference Paper

2016

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Rawstron, A. C., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F. J., Bishop, R., . . . Hillmen, P. (2016). Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2049.2049

DOI
10.1182/blood.V128.22.2049.2049
Conference Paper

Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma

Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Zinzani, P. L., . . . Wagner-Johnston, N. D. (2016). Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.1218.1218

DOI
10.1182/blood.V128.22.1218.1218
Conference Paper

Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot

Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Alsolami, R., . . . Schuh, A. (2016). Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2022.2022

DOI
10.1182/blood.V128.22.2022.2022
Conference Paper

Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia

Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2016). Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.192.192

DOI
10.1182/blood.V128.22.192.192
Conference Paper

Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome

Nwosu, A. C., Morris, L., Mayland, C., Mason, S., Pettitt, A., & Ellershaw, J. (2016). Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome. BMJ SUPPORTIVE & PALLIATIVE CARE, 6(3), 369-372. doi:10.1136/bmjspcare-2015-000991

DOI
10.1136/bmjspcare-2015-000991
Journal article

Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment.

Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A., Sharman, J. P., Ysebaert, L., . . . Furman, R. R. (2016). Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.7531

DOI
10.1200/JCO.2016.34.15_suppl.7531
Conference Paper

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., . . . CLL, E. R. I. C. E. R. I. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30, 929-936. doi:10.1038/leu.2015.313

DOI
10.1038/leu.2015.313
Journal article

DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES

Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A. R., Sharman, J. P., Ysebaert, L., . . . Stilgenbauer, S. (2016). DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES. In HAEMATOLOGICA Vol. 101 (pp. 54). Retrieved from https://www.webofscience.com/

Conference Paper

2015

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus

Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2015). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLOS ONE, 10(11). doi:10.1371/journal.pone.0142379

DOI
10.1371/journal.pone.0142379
Journal article

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Guieze, R., Robbe, P., Clifford, R., de Guibert, S., Pereira, B., Timbs, A., . . . Schuh, A. (2015). Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. BLOOD, 126(18), 2110-2117. doi:10.1182/blood-2015-05-647578

DOI
10.1182/blood-2015-05-647578
Journal article

Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia

Pagel, J. M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Hillmen, P., . . . Hallek, M. J. (2015). Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, S201-S202. doi:10.1016/j.clml.2015.04.062

DOI
10.1016/j.clml.2015.04.062
Journal article

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., . . . Investigators, C. O. M. P. L. E. M. E. N. T. 1. S. (2015). Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. The Lancet, 385(9980), 1873-1883. doi:10.1016/S0140-6736(15)60027-7

DOI
10.1016/S0140-6736(15)60027-7
Journal article

Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1phosphate receptors and integrins

Middle, S., Coupland, S. E., Taktak, A., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015). Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1phosphate receptors and integrins. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 4. doi:10.1186/s40164-015-0004-3

DOI
10.1186/s40164-015-0004-3
Journal article

Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia

Eagle, G., Zhuang, J., Jenkins, R., Till, K., Jithesh, P., Lin, K., . . . Pettitt, A. (2015). Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia. Molecular and Cellular Proteomics, 14(4), 933-945. doi:10.1074/mcp.M114.044479

DOI
10.1074/mcp.M114.044479
Journal article

Common variation at 12q24.13 (<i>OAS3</i>) influences chronic lymphocytic leukemia risk

Sava, G. P., Speedy, H. E., Di Bernardo, M. C., Dyer, M. J. S., Holroyd, A., Sunter, N. J., . . . Houlston, R. S. (2015). Common variation at 12q24.13 (<i>OAS3</i>) influences chronic lymphocytic leukemia risk. LEUKEMIA, 29(3), 748-751. doi:10.1038/leu.2014.311

DOI
10.1038/leu.2014.311
Journal article

Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells

Till, K. J., Pettitt, A., & Slupsky, J. (2015). Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells. Journal of Immunology, 194(5), 2439-2446. doi:10.4049/jimmunol.1402304

DOI
10.4049/jimmunol.1402304
Journal article

A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR

Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR. In HAEMATOLOGICA Vol. 100 (pp. 222-223). Retrieved from https://www.webofscience.com/

Conference Paper

Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia

Zhuang, J., Chapman, E., Stockman, P., Davies, B., & Pettitt, A. (2015). Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 56, 16-18. Retrieved from https://www.webofscience.com/

Journal article

Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., . . . Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 53). Retrieved from https://www.webofscience.com/

Conference Paper

Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair

Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 73). Retrieved from https://www.webofscience.com/

Conference Paper

OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED

Alishlash, O., Pettitt, A., Coupland, S., & Lin, K. (2015). OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED. In HAEMATOLOGICA Vol. 100 (pp. 765). Retrieved from https://www.webofscience.com/

Conference Paper

Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 μm tissue are required

Alishlash, O., Coupland, S., Pettitt, A., & Lin, K. (2015). Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 μm tissue are required. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 74-75). Retrieved from https://www.webofscience.com/

Conference Paper

Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials

Munir, T., Cohen, D., Pocock, C., Rawstron, A., Collet, L., McParland, L., . . . Hillmen, P. (2015). Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials. LEUKEMIA & LYMPHOMA, 56, 26-27. Retrieved from https://www.webofscience.com/

Journal article

SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME

Eyre, T., Clifford, R., Bloor, A., Boyle, L., Cabes, M., Collins, G., . . . Schuh, A. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. In HAEMATOLOGICA Vol. 100 (pp. 109). Retrieved from https://www.webofscience.com/

Conference Paper

2014

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Rawstron, A., Fazi, C., Villamor, N., Delgado, J., Letestu, R., Cymbalista, F., . . . Ghia, P. (2014). A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. BLOOD, 124(21). Retrieved from https://www.webofscience.com/

Journal article

Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy

Hargreaves, C., Iriyama, C., Rose-Zerilli, M. J. J., Lee, C., Potter, K., Ganderton, R., . . . Strefford, J. C. (2014). Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy. BLOOD, 124(21). Retrieved from https://www.webofscience.com/

Journal article

Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing

Robbe, P., Guieze, R., Clifford, R. M., de Guibert, S., Timbs, A., Dilhuydy, M. -S., . . . Tournilhac, O. (2014). Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays

Knight, S. J. L., Clifford, R., Robbe, P., Ramos, S. D. C., Burns, A., Timbs, A. T., . . . Shuh, A. (2014). The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays. BLOOD, 124(21). Retrieved from https://www.webofscience.com/

Journal article

Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia

Eagle, G. L., Jenkins, R. E., Till, K. J., Puthen, J., Lin, K., Johnson, G. G., . . . Pettitt, A. R. (2014). Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials

Clifford, R. M., Robbe, P., Weller, S., Timbs, A. T., Titsias, M., Burns, A., . . . Schuh, A. (2014). Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Conference Paper

Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis

Zhuang, J., Laing, N., Oates, M., Lin, K., Johnson, G., & Pettitt, A. R. (2014). Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis. Pharmacology Research & Perspectives, 2(6). doi:10.1002/prp2.81

DOI
10.1002/prp2.81
Journal article

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach

te Raa, G. D., Malcikova, J., Mraz, M., Trbusek, M., Le Garff-Tavernier, M., Merle-Beral, H., . . . Kater, A. P. (2014). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRITISH JOURNAL OF HAEMATOLOGY, 167(4), 565-569. doi:10.1111/bjh.13006

DOI
10.1111/bjh.13006
Journal article

Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia

Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043

DOI
10.1111/bjh.13043
Journal article

Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.

Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., . . . Wagner, L. I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7099

DOI
10.1200/jco.2014.32.15_suppl.7099
Conference Paper

Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7012

DOI
10.1200/jco.2014.32.15_suppl.7012
Conference Paper

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Hillmen, P., Gribben, J. G., Follows, G. A., Milligan, D., Sayala, H. A., Moreton, P., . . . Pocock, C. F. E. (2014). Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. Journal of Clinical Oncology, 32(12), 1236-1241. doi:10.1200/JCO.2013.49.6547

DOI
10.1200/JCO.2013.49.6547
Journal article

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 370, 997-1007. doi:10.1056/NEJMoa1315226

DOI
10.1056/NEJMoa1315226
Journal article

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage

Clifford, R., Louis, T., Robbe, P., Ackroyd, S., Burns, A., Timbs, A. T., . . . Schuh, A. (2014). SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. BLOOD, 123(7), 1021-1031. doi:10.1182/blood-2013-04-490847

DOI
10.1182/blood-2013-04-490847
Journal article

EBV-associated post-transplant lymphoproliferative disorder following <i>in vivo</i> T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

Fox, C. P., Burns, D., Parker, A. N., Peggs, K. S., Harvey, C. M., Natarajan, S., . . . Chaganti, S. (2014). EBV-associated post-transplant lymphoproliferative disorder following <i>in vivo</i> T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. BONE MARROW TRANSPLANTATION, 49(2), 280-286. doi:10.1038/bmt.2013.170

DOI
10.1038/bmt.2013.170
Journal article

2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., . . . Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. ONCOLOGY RESEARCH AND TREATMENT, 37, 183. Retrieved from https://www.webofscience.com/

Journal article

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

Speedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., . . . Houlston, R. S. (2014). A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. NATURE GENETICS, 46(01), 56-60. doi:10.1038/ng.2843

DOI
10.1038/ng.2843
Journal article

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375)

Hillmen, P., Furman, R., Sharmann, J., Coutre, S., Cheson, B., Pagel, J., . . . O'Brien, S. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 3). Retrieved from https://www.webofscience.com/

Conference Paper

COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA

Taylor, D., Angelillo, P., Ward, C., Collins, D., Salim, R., Pettitt, A., . . . Kalakonda, N. (2014). COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA. In HAEMATOLOGICA Vol. 99 (pp. 701). Retrieved from https://www.webofscience.com/

Conference Paper

HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS

Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., . . . Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. In HAEMATOLOGICA Vol. 99 (pp. 63). Retrieved from https://www.webofscience.com/

Conference Paper

Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review)

Till, K. J., Coupland, S. E., & Pettitt, A. R. (2014). Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review). INTERNATIONAL JOURNAL OF ONCOLOGY, 45(1), 5-12. doi:10.3892/ijo.2014.2395

DOI
10.3892/ijo.2014.2395
Journal article

ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS

Munir, T., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS. In HAEMATOLOGICA Vol. 99 (pp. 54). Retrieved from https://www.webofscience.com/

Conference Paper

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)

Hillmen, P., Pettitt, A., Schuh, A., Milligan, D., Bowles, K., Bareford, D., . . . McKeown, A. (2014). Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 19-20). Retrieved from https://www.webofscience.com/

Conference Paper

PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL

Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., . . . Cheson, B. D. (2014). PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL. In HAEMATOLOGICA Vol. 99 (pp. 55). Retrieved from https://www.webofscience.com/

Conference Paper

Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., . . . Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. ONCOLOGY RESEARCH AND TREATMENT, 37, 52-53. Retrieved from https://www.webofscience.com/

Journal article

Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses

Bloor, A. J. C., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 18). Retrieved from https://www.webofscience.com/

Conference Paper

SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL

Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. In HAEMATOLOGICA Vol. 99 (pp. 249-250). Retrieved from https://www.webofscience.com/

Conference Paper

Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?

E. Clapham, C., R. Pettitt, A., & R. Slupsky, J. (n.d.). Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?. Journal of Hematology And Oncology Research, 1(1), 7-23. doi:10.14302/issn.2372-6601.jhor-13-346

DOI
10.14302/issn.2372-6601.jhor-13-346
Journal article

2013

<i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). <i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. BLOOD, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666

DOI
10.1182/blood-2013-07-516666
Journal article

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia

Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666

DOI
10.1182/blood-2013-07-516666
Journal article

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). In BLOOD Vol. 122. doi:10.1182/blood.V122.21.LBA-6.LBA-6

DOI
10.1182/blood.V122.21.LBA-6.LBA-6
Conference Paper

Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.

Pye, D. S., Rubio, I., Pusch, R., Lin, K., Pettitt, A. R., & Till, K. J. (2013). Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.. Journal of immunology (Baltimore, Md. : 1950), 191(3), 1496-1504. doi:10.4049/jimmunol.1203484

DOI
10.4049/jimmunol.1203484
Journal article

Abstracts of the 53rd Annual Scientific Meeting of the British Society for Haematology. April 15-17, 2013. Liverpool, United Kingdom.

Abstracts of the 53rd Annual Scientific Meeting of the British Society for Haematology. April 15-17, 2013. Liverpool, United Kingdom. (2013). British journal of haematology, 161 Suppl 1, 1-87. doi:10.1111/bjh.12263

DOI
10.1111/bjh.12263
Journal article

2012

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak

Melarangi, T., Zhuang, J., Lin, K., Rockliffe, N., Bosanquet, A. G., Oates, M., . . . Pettitt, A. R. (2012). Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. CELL DEATH & DISEASE, 3. doi:10.1038/cddis.2012.102

DOI
10.1038/cddis.2012.102
Journal article

Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration

Lin, K., Adamson, J., Johnson, G. G., Carter, A., Oates, M., Wade, R., . . . Pettitt, A. R. (2012). Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. CLINICAL CANCER RESEARCH, 18(15), 4191-4200. doi:10.1158/1078-0432.CCR-11-2936

DOI
10.1158/1078-0432.CCR-11-2936
Journal article

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial

Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1647-1655. doi:10.1200/JCO.2011.35.9695

DOI
10.1200/JCO.2011.35.9695
Journal article

Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies

Zhuang, J., & Pettitt, A. R. (2012). Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies. Current Topics in Steroid Research, 9, 93-109.

Journal article

The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p

Lin, K., Lane, B., Carter, A., Johnson, G. G., Onwuazor, O., Oates, M., . . . Pettitt, A. R. (2012). The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p. British Journal of Haematology.

Journal article

2011

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p

Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. EUROPEAN JOURNAL OF HAEMATOLOGY, 87(4), 372-375. doi:10.1111/j.1600-0609.2011.01667.x

DOI
10.1111/j.1600-0609.2011.01667.x
Journal article

A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

Hillmen, P., Cohen, D., Cocks, K., Pettitt, A. R., Sayala, H., Rawstrom, A., . . . Pocock, C. (2011). A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 152(5), 570-578.

Journal article

Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication

Evans, J., Ziebland, S., & Pettitt, A. R. (2011). Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication. European Journal of Cancer Care, 1365-2354.

Journal article

2010

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.

Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., . . . European Research Initiative on CLL (ERIC). (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.. Leukemia, 24(12), 2072-2079. doi:10.1038/leu.2010.208

DOI
10.1038/leu.2010.208
Journal article

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080-3088. doi:10.1182/blood-2010-05-286856

DOI
10.1182/blood-2010-05-286856
Journal article

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

Zhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., . . . Pettitt, A. R. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(1), 110-118. doi:10.3324/haematol.2009.010272

DOI
10.3324/haematol.2009.010272
Journal article

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

Zhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., . . . Pettitt, A. R. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(1), 110-118. doi:10.3324/haematol.2009.010272

DOI
10.3324/haematol.2009.010272
Journal article

Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia

Rees-Unwin, K. S., Faragher, R., Unwin, R. D., Adams, J., Brown, P. J., Buckle, A. M., . . . Burthem, J. (2010). Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. British Journal of Haematology, 148(4), 534-543.

Journal article

Variant <i>IRF4/MUM1</i> associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia

Allan, J. M., Sunter, N. J., Bailey, J. R., Pettitt, A. R., Harris, R. J., Pepper, C., . . . Allsup, D. J. (2010). Variant <i>IRF4/MUM1</i> associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. LEUKEMIA, 24(4), 877-881. doi:10.1038/leu.2009.298

DOI
10.1038/leu.2009.298
Journal article

p53 dysfunction in chronic lymphocytic leukemia

Pospisilova, S., & Pettitt, A. R. (2010). p53 dysfunction in chronic lymphocytic leukemia. In K. Stamatopoulos, P. Ghia, & R. Rosenquist (Eds.), New Biological Prognostic Markers in Chronic Lymphocytic Leukemia (pp. 73-95). Italy: Walter Kluyers Health Ltd.

Chapter

2009

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

Hoskin, P. J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B. W., . . . Johnson, P. W. M. (2009). Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(32), 5390-5396. doi:10.1200/jco.2009.23.3239

DOI
10.1200/jco.2009.23.3239
Journal article

A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the <i>p21</i> Gene

Johnson, G. G., Sherrington, P. D., Carter, A., Lin, K., Liloglou, T., Field, J. K., & Pettitt, A. R. (2009). A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the <i>p21</i> Gene. CANCER RESEARCH, 69(12), 5210-5217. doi:10.1158/0008-5472.CAN-09-0627

DOI
10.1158/0008-5472.CAN-09-0627
Journal article

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.

Faderl, S., Ferrajoli, A., Frankfurt, O., & Pettitt, A. (2009). Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.. Leukemia, 23(3), 457-466. doi:10.1038/leu.2008.322

DOI
10.1038/leu.2008.322
Journal article

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.

Robinson, S. P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., . . . Lymphoma Working Party of the EBMT. (2009). Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.. Haematologica, 94(2), 230-238. doi:10.3324/haematol.13441

DOI
10.3324/haematol.13441
Journal article

Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL

Pettitt, A. R., Matutes, E., Dearden, C., Oscier, D. G., Carruthers, S., Dodd, S., . . . Hillmen, P. (2009). Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Hematologica, 94, 351a.

Journal article

2008

A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Di Bernardo, M. C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., . . . Houlston, R. S. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.. Nature genetics, 40(10), 1204-1210. doi:10.1038/ng.219

DOI
10.1038/ng.219
Journal article

DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia

Willmore, E., Elliott, S. L., Mainou-Fowler, T., Summerfield, G. R., Jackson, G. H., O'Neill, F., . . . Durkacz, B. W. (2008). DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. CLINICAL CANCER RESEARCH, 14(12), 3984-3992. doi:10.1158/1078-0432.CCR-07-5158

DOI
10.1158/1078-0432.CCR-07-5158
Journal article

Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.

Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2008). Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.. Oncogene, 27(17), 2445-2455. doi:10.1038/sj.onc.1210893

DOI
10.1038/sj.onc.1210893
Journal article

Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.

Pettitt, A. R. (2008). Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.. Leukemia & lymphoma, 49(10), 1843-1845. doi:10.1080/10428190802455883

DOI
10.1080/10428190802455883
Journal article

2007

The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.

Thachil, J., Jadhav, V., Gautam, M., McKew, S., Arumainathan, A., Collins, D., . . . Pettitt, A. (2007). The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.. British journal of haematology, 138(4), 559-560. doi:10.1111/j.1365-2141.2007.06687.x

DOI
10.1111/j.1365-2141.2007.06687.x
Journal article

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R. F., . . . NCRI Chronic Lymphocytic Leukaemia Working Group. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.. Lancet (London, England), 370(9583), 230-239. doi:10.1016/s0140-6736(07)61125-8

DOI
10.1016/s0140-6736(07)61125-8
Journal article

The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia

Kay, N. E., O'Brien, S. M., Pettitt, A. R., & Stilgenbauer, S. (2007). The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. LEUKEMIA, 21(9), 1885-1891. doi:10.1038/sj.leu.2404802

DOI
10.1038/sj.leu.2404802
Journal article

2006

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.

Pettitt, A. R., Matutes, E., & Oscier, D. (2006). Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.. Leukemia, 20(8), 1441-1445. doi:10.1038/sj.leu.2404265

DOI
10.1038/sj.leu.2404265
Journal article

Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.

Carter, A., Lin, K., Sherrington, P. D., Atherton, M., Pearson, K., Douglas, A., . . . Pettitt, A. R. (2006). Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.. Leukemia, 20(4), 737-740. doi:10.1038/sj.leu.2404120

DOI
10.1038/sj.leu.2404120
Journal article

2005

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.

Romanov, V. V., James, C. H., Sherrington, P. D., & Pettitt, A. R. (2005). Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.. Oncogene, 24(45), 6855-6860. doi:10.1038/sj.onc.1208895

DOI
10.1038/sj.onc.1208895
Journal article

Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance.

Lane, B. S., Mensah, A. A., Lin, K., Pettitt, A. R., & Sherrington, P. D. (2005). Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance.. Leukemia, 19(5), 741-749. doi:10.1038/sj.leu.2403720

DOI
10.1038/sj.leu.2403720
Journal article

2004

Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.

Carter, A., Lin, K., Sherrington, P. D., & Pettitt, A. R. (2004). Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.. British journal of haematology, 127(4), 425-428. doi:10.1111/j.1365-2141.2004.05223.x

DOI
10.1111/j.1365-2141.2004.05223.x
Journal article

Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death.

Kamiguti, A. S., Moran, E. C., & Pettitt, A. R. (2004). Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death.. British journal of haematology, 127(2), 236-238. doi:10.1111/j.1365-2141.2004.05184.x

DOI
10.1111/j.1365-2141.2004.05184.x
Journal article

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.

Jones, G. G., Reaper, P. M., Pettitt, A. R., & Sherrington, P. D. (2004). The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.. Oncogene, 23(10), 1911-1921. doi:10.1038/sj.onc.1207318

DOI
10.1038/sj.onc.1207318
Journal article

Natural history of CLL: Current thinking

Pettitt, A. R., Sherrington, P., Allsup, D. J., Matrai, Z., Cawley, J. C., & Zuzel, M. (2004). Natural history of CLL: Current thinking. In A. Miles (Ed.), UK Key Advances in Clinical Practice Series. Key Advances in the Effective Management of Chronic Lymphocytic Leukaemia (pp. not known at present). not known at present: not known at present.

Chapter

2003

High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.

Lin, K., Manocha, S., Harris, R. J., Matrai, Z., Sherrington, P. D., & Pettitt, A. R. (2003). High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.. Blood, 102(3), 1145-1146. doi:10.1182/blood-2003-04-1289

DOI
10.1182/blood-2003-04-1289
Journal article

Mechanism of action of purine analogues in chronic lymphocytic leukaemia.

Pettitt, A. R. (2003). Mechanism of action of purine analogues in chronic lymphocytic leukaemia.. British journal of haematology, 121(5), 692-702. doi:10.1046/j.1365-2141.2003.04336.x

DOI
10.1046/j.1365-2141.2003.04336.x
Journal article

Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.

Manocha, S., Matrai, Z., Osthoff, M., Carter, A., & Pettitt, A. R. (2003). Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.. Leukemia & lymphoma, 44(5), 797-800. doi:10.1080/1042819031000068034

DOI
10.1080/1042819031000068034
Journal article

2002

Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.

Lin, K., Sherrington, P. D., Dennis, M., Matrai, Z., Cawley, J. C., & Pettitt, A. R. (2002). Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.. Blood, 100(4), 1404-1409. doi:10.1182/blood-2001-11-0066

DOI
10.1182/blood-2001-11-0066
Journal article

Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion

Baker, P. K., Pettitt, A. R., Slupsky, J. R., Chen, H. J., Glenn, M. A., Zuzel, M., & Cawley, J. C. (2002). Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion. BLOOD, 100(2), 647-653. doi:10.1182/blood.V100.2.647

DOI
10.1182/blood.V100.2.647
Journal article

Cytoprotective antioxidant activity of serum albumin and autocrine catalase in

Moran, E. C., Kamiguti, A. S., Cawley, J. C., & Pettitt, A. R. (2002). Cytoprotective antioxidant activity of serum albumin and autocrine catalase in. Br J Haematol., 116(2), 316-328.

Journal article

Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion

Baker, P. K., Pettitt, A. R., Slupsky, J. R., Chen, H. J., Glenn, M. A., Zuzel, M., & Cawley, J. C. (2002). Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood, 100(2), 647-653.

Journal article

2001

Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro.

Pettitt, A. R., Moran, E. C., & Cawley, J. C. (2001). Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro.. Leukemia research, 25(11), 1003-1012. doi:10.1016/s0145-2126(01)00067-4

DOI
10.1016/s0145-2126(01)00067-4
Journal article

p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.

Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M., & Stankovic, T. (2001). p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.. Blood, 98(3), 814-822. doi:10.1182/blood.v98.3.814

DOI
10.1182/blood.v98.3.814
Journal article

CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.

Matrai, Z., Lin, K., Dennis, M., Sherrington, P., Zuzel, M., Pettitt, A. R., & Cawley, J. C. (2001). CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.. Blood, 97(6), 1902-1903.

Journal article

2000

Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.

Pettitt, A. R., & Cawley, J. C. (2000). Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.. British journal of haematology, 109(4), 800-804. doi:10.1046/j.1365-2141.2000.02068.x

DOI
10.1046/j.1365-2141.2000.02068.x
Journal article

Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.

Harris, R. J., Pettitt, A. R., Schmutz, C., Sherrington, P. D., Zuzel, M., Cawley, J. C., & Griffiths, S. D. (2000). Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.. Journal of immunology (Baltimore, Md. : 1950), 164(7), 3887-3893. doi:10.4049/jimmunol.164.7.3887

DOI
10.4049/jimmunol.164.7.3887
Journal article

Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.

Pettitt, A. R., Sherrington, P. D., & Cawley, J. C. (2000). Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.. Cancer Res., 60(15), 4187-4193.

Journal article

1999

The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.

Pettitt, A. R., Sherrington, P. D., & Cawley, J. C. (1999). The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.. British journal of haematology, 106(4), 1049-1051. doi:10.1046/j.1365-2141.1999.01649.x

DOI
10.1046/j.1365-2141.1999.01649.x
Journal article

Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.

Pettitt, A. R., Clarke, A. R., Cawley, J. C., & Griffiths, S. D. (1999). Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.. British journal of haematology, 105(4), 986-988. doi:10.1046/j.1365-2141.1999.01448.x

DOI
10.1046/j.1365-2141.1999.01448.x
Journal article

Hairy-cell leukaemia: biology and management.

Pettitt, A. R., Zuzel, M., & Cawley, J. C. (1999). Hairy-cell leukaemia: biology and management.. Br J Haematol., 106(1), 2-8.

Journal article

1995

An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants.

Pettitt, A. R., Grace, P., & Chu, P. (1995). An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants.. Clin Lab Haematol., 17(2), 125-129.

Journal article

1994

Thrombotic microangiopathy following bone marrow transplantation.

Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone marrow transplantation, 14(4), 495-504.

Journal article

Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.

Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone marrow transplantation, 13(2), 225-227.

Journal article